Personalized Oncology - Why Tissue Is the Issue When Characterizing Tumor Expression Profiles, New Webinar Hosted by Xtalks
TORONTO, November 9, 2018 (Newswire.com) - The future of cancer therapy relies on a personalized oncology approach by understanding individual variances and making therapy decisions accordingly. In the past 10 years, clinical researchers have primarily searched for drug targets using DNA sequencing to identify therapy-relevant mutations. However, it has become clear that it is impossible to efficiently personalize oncology by only focusing on genetic events in cancers. As important as understanding genetic events are, it is much more important to understand phenotypic variations which represent the complexity of the disease and eventually provide specific drug targets.
However, cancer phenotypes are a result of many factors of which most are preserved in tumor tissue, such as cellular interactions, growth factors and signaling pathways, immune-cell composition and activity.
A major challenge for researchers and physicians in personalized oncology is that phenotypic characterization depends on tumor tissue obtained either by surgical removal or a biopsy. Further complicating matters is the fact that cancer cells change expression profiles, such as RNA, protein and phosphoproteins, within minutes of when tissue is removed from the body. Therefore, it is mandatory to establish a clinical workflow (which often does not exist) that assures tissue collection is performed under SOP guidance, allowing for cellular and molecular tissue integrity. One example is an identical and rapid processing of tissue already in the surgical suite to reduce ischemia times to as close to zero as possible. Furthermore, a stringent QC process is needed to control the tissue quality and its ability to provide clinically reliable data. Otherwise, numerous biological data points are lost or systematically wrong and it is impossible to successfully personalize oncology for patient care.
This live webinar upcoming on Tuesday, Nov. 27, 2018, at 10 a.m. EST (3 p.m. GMT/UK) will address the challenges in personalized oncology to obtain clinically reliable data for the understanding of individual cancer. A special focus will be put on the clinical workflow that assures tissue quality and the QC options to qualify tissue for obtaining clinically reliable data.
Join Indivumed’s expert speakers Dr. Hartmut Juhl, founder and CEO, and Dr. Bernd Gromoll, Surgical Pathologist/Histopathologist, for an insightful and interactive presentation.
For more information about this complimentary webinar, visit Personalized Oncology – Why Tissue Is the Issue When Characterizing Tumor Expression Profiles.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Tel: +1 (416) 977-6555 ext 352
Categories: Pharmaceuticals and Biotech